SCHEMBL27454822

SCHEMBL27454822

O=C1CCN(c2cccc3c2CCN3[C@H]2CCC(=O)NC2=O)CC1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CRBN Q96SW2 18/20 0.47
▸ DDB1 Q16531 11/20 0.46
▸ IKZF3 Q9UKT9 5/20 0.46
▸ TNF P01375 2/20 0.46
▸ IL1B P01584 2/20 0.46
▸ IKZF1 Q13422 2/20 0.46
▸ BRD4 O60885 1/20 0.46
▸ ALDH1A1 P00352 2/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ GAA P10253 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ CHRM2 P08172 1/20 0.44
▸ OPRM1 P35372 1/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ TBXA2R P21731 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26930449 0.89 CRBN (0.46) CRBNDDB1IKZF3TNFIL1B
SCHEMBL26930466 0.88 CRBN (0.48) CRBNDDB1IKZF3TNFIL1B
SCHEMBL26930503 0.88 CRBN (0.48) CRBNDDB1IKZF3TNFIL1B
SCHEMBL30659363 0.88 CRBN (0.48) CRBNDDB1IKZF3TNFIL1B
SCHEMBL31542343 0.86 CRBN (0.46) CRBNDDB1IKZF3TNFIL1B
SCHEMBL30659445 0.85 CRBN (0.46) CRBNDDB1IKZF3TNFIL1B
SCHEMBL30659404 0.85 CRBN (0.46) CRBNDDB1IKZF3TNFIL1B
SCHEMBL26930523 0.85 CRBN (0.43) CRBNDDB1IKZF3TNFIL1B
SCHEMBL27454823 0.85 CRBN (0.43) CRBNDDB1IKZF3TNFIL1B
SCHEMBL26930520 0.85 CRBN (0.46) CRBNDDB1IKZF3TNFIL1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4539849-A1 COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 C4 Therapeutics, Inc. (US) 2025-04-23 — — EP disclosed
US-20250121070-A1 COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 C4 THERAPEUTICS, INC. (US) 2025-04-17 — — US disclosed
WO-2023244764-A1 COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 C4 THERAPEUTICS, INC. (US) 2023-12-21 — — WO disclosed
WO-2023244764-A1 COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 C4 THERAPEUTICS, INC. (US) 2023-12-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250121070-A1 COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 SMARCA2, SMARCE1, SMARCA1 CRBN 29/4885DDB1 320/4885IKZF3 664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback